BLDV and Cann10 North America Synchronize Objectives
Blue Diamond Ventures Inc. will Benefit from Additional Resources
April 9th, 2018 – Blue Diamond Ventures Inc, (OTC PK: BLDV) Chicago, IL.
Cann10 North America Holdings LTD. and Blue Diamond Ventures Inc., the largest shareholder in Cann10 North America, are working toward combining their efforts in the most strategic way.
Cann10 Israel Ownership controls 51% of Cann10 North America, and the primary initial objectives include, offering Professional Medical Cannabis Education, and running the industry’s premiere Medical Cannabis Industry Conferences in North America.
“Cann10 North America & BLDV will raise money with a Tier 1 Reg A+” says Josh Alper, BLDV CEO. “As an Alternative Reporting – Pink Sheet Company – BLDV is eligible for a Reg A+ Offering, and now with the support of Cann10 NA, we can get it done” “Most of the funds raised will be used to invest in the Cann10 XL, tosecure the pipeline of Cannabis Innovations and Technology from Israel, for the North America Company and some to produce the first CannX Conference in North America in 2019.
Cann10 is a Global Partner with activity in ten countries with an aggressive strategy of participating in licenses and ventures of all types, but with a long-term focus on Targeted Therapies, Specific Formulations and Medical Devices providing a bridge to the BioCannacuetical on the road to Biopharmaceutical.
Yossi Bornstein, CEO of Shizim Ltd, and Chairman of Cann10 International currently serves on the board of multiple Biotech companies including one traded on the Nasdaq, and Kobi Caspi CFO of Shizim are both expected to join the BLDV Board of Directors.
Cann10 International recognizes the potential of the public aspects of BLDV. The two years spent by the Alper Group of Companies cleaning up the books, structuring the operations and defining the offerings of the companycreated the conditions that will drive the effort forward.
The parties will announce further steps as they are confirmed. About BLDV: Blue Diamond Ventures, Inc. is a diversified customer centric Management / Holding Company; Blue Diamond Ventures, Inc. seeks opportunities in medical cannabis markets and is driven by critical thinking, the scientific method and compassionate ways to deliver sustainable results
About Cann10: Cann10 is one of the Leading Medical Cannabis Groups in Israel. They create and produce highly recognized Professional Cannabis Education Programs, including the CannX Medical Conferences in Israel, and the Cann10 XL a focused accelerator, offering selected entrepreneurs the advantages of high quality infrastructures, facilities, team, network, know-how and professional mentoring, tailored to support successful development, fund raising and commercialization of new technologies in this emerging field.
A collaboration between a leading Israeli authorized medical cannabis farm, and a leading Israeli holding and services group, Cann10 combines the respective expertise in the fields of medical cannabis and commercialization of medical devices and drugs, to support the introduction of new high value related products.
Contact: Blue Diamond Ventures Inc. / Cann10 North America 535 N. Michigan Avenue, Suite 3001, Chicago, Illinois, 60611 Joshua B. Alper Chief Executive Officer BLDV – Managing Director of Cann10 NA (844) 637-6377 info@bldvinc.com www.bldvinc.com
CEO Joshua Alper of Blue Diamond Ventures, Inc. (OTCPink: BLDV), rejoins Uptick Newswire to discuss delayed financial reports, various consulting projects related to medical marijuana, and upcoming merger with Cann10.
Key extracts from the June 2018 interview (from YT clip above):
1. 0:59 > BLDV is in the process of bringing in a new financial team for the Cann10 merger which includes a new accountant and a new attorney. The yield sign and hold up of filings is due to the change in the accounting team which should be cleared by July 15.
- I do not think you bring in a new accountant and lawyer for just any merger, I think something of value is coming with the merger for BLDV to incur these additional costs. Highlights of the related 6/12/18 PR:
2. 1:42 > BLDV is trying to systematically build relationships in the medical cannabis industry. As BLDV does this, the connection to and merger with Cann10 is going to allow BLDV to take the next step financially.
- Notice how the BLDV CEO mentions the merger and the connection to Cann10 that will enable BLDV to take the next step financially. I found this part of the interview to be the most important for me to hear. As I have stated before, Cann10 did not chose to get involved with BLDV for no reason. Cann10 chose BLDV, which is currently an OTC Pink company, to enter North America; you do not see this often with an otc ticker. Specifically, I think this comment in the interview gives us insight into to one of the potential advantages to BLDV from the merger which can be additional financial capacity. It will be interesting to see if this potential additional financial capacity translates into value for BLDV’s Canadian strategic partners.
3. 2:06, 12:16 > Interviewer indicates that the BLDV CEO is one of the hardest working CEOs on the OTC markets
- As a shareholder, this comment is in line with my understanding and is good to hear even though BLDV is a client of the interviewer.
4. 2:46 > Fresno 20 acres project: Land is owned by an Israeli gentleman who has a connection with Cann10 and BLDV will be assisting in property development of a grow park
- Notice how the BLDV CEO indicates that the project comes from the connection with Cann10. I think this is important to give us a perspective into the support and motivation of Cann10 to help BLDV grow through its Israeli connections worldwide. Also, I think it helps explain the motivation to merge Cann10 NA into BLDV. I think BLDV’s future growth will be driven in part by Cann10’s Israeli connections.
5. 3:39 > BLDV CEO explains why they are taking on various projects and how the consulting projects give BLDV the opportunity to engage with clients all over North America. Further, he goes on to explain how Cann10 is at the core of the relationship and it will provide licensing of its products and/or technologies in these projects.
- I interpret this part of the interview as indicating that BLDV is getting a foot in the door with these projects that will generate future secondary revenues for BLDV and Cann10 in the form of licensing products, technologies, services and other consulting support <<< This is key.
- Notice how BLDV is engaging with clients all over North America is in alignment with Cann10’s objective to enter North America which will be facilitated through the upcoming merger. If you look at only the titles of BLDV’s PRs dating back to January you will see the pattern/story developing of how BLDV is synchronizing its operations with Cann10 which was included in the title of the 4/9/18 PR, see highlights here:
6. 4:10 > Cann10 is developed out of a biotech company in Israel named Shizim which applied skills to the cannabis industry. Cann10 is a parallel effort which is now active in 10 countries worldwide. BLDV is a Colorado corporation that is merging with Cann10 NA as a Canadian company which gives BLDV the flexibility of listing on the CSE without breaking the existing BLDV structure. A lot of ground work has to be completed for the merger to be in compliance with FINRA and SEC legislation.
- I interpret the use of the words “flexibility” and "without breaking the existing structure" in this part of the interview to mean that BLDV may have the option to list on both sides of the northern border in the future.
7. 6:18 > Cann10 in Israel generates big numbers and they are involved in millions of dollars. Cann10 is involved in the licensing of technologies focused on the pharmaceutical company and a lot of companies are circling back to medical formulations. The Virginia project is an example of these project applications which is Cann10’s strength, see highlights of 5/28/18 PR:
- It will be interesting to see what kinds of returns these cannabis pharma projects will generate.
8. 7:20 > Reg. A+ offering of $3 million will be done in conjunction with the merger of the companies and the expansion of BLDV's governance. Since BLDV is still a non-reporting PinkSheet company, the offering will be completed by September 1 when the first audited statement is filed.
- I find that the governance aspect is being mentioned often which I interpret that Cann10 will have input into how the merged entity will be run.
- I am not familiar with Reg. A+ offerings, if anyone has any constructive thoughts please share them. Here are some links with some general information:
9. 9:20 > BLDV has to take a hard look at how current holdings such as Cannabis Clean will contribute to the BLDV stock value. BLDV is focused on the pharmaceutical biotech direction. BLDV is a science driven company with Cann10 by focusing on targeted therapies and treatments that the medical profession is looking for.
- I think this interview is demonstrating how BLDV is now making much needed realistic decisions on streamlining its operations in order to add long-term value to the stock, such as focusing on the Cann10 approach. I think making realistic decisions and adding value to the stock set the tone and are the purpose of this interview.
10. 11:35 > BLDV has respect for the shareholders during this difficult transition. BLDV is not in this for short-term financial gain and they are committed to creating long-term value for the stock.
- This is one of the reasons why I own BLDV shares combined with the fact that BLDV does not have any convertible notes on its unaudited financial statements as of 12/31/17.
News 
Market Data 
Discover 
